Inhibition of the STAT5/Pim Kinase Axis Enhances Cytotoxic Effects of Proteasome Inhibitors on FLT3-ITD–Positive AML Cells by Cooperatively Inhibiting the mTORC1/4EBP1/S6K/Mcl-1 Pathway-Reference-Cited by-同舟云学术

Inhibition of the STAT5/Pim Kinase Axis Enhances Cytotoxic Effects of Proteasome Inhibitors on FLT3-ITD–Positive AML Cells by Cooperatively Inhibiting the mTORC1/4EBP1/S6K/Mcl-1 Pathway

Published:2019-02 Issue:2 Volume:12 Page:336-349
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Nogami Ayako,Okada Keigo,Ishida Shinya,Akiyama Hiroki,Umezawa Yoshihiro,Miura Osamu

Funder

Ministry of Education, Culture, Sports, Science and Technology of Japan

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference35 articles.

1. FLT3 inhibitors: clinical potential in acute myeloid leukemia;Hospital;OncoTargets Ther,2017

2. Structural and functional alterations of FLT3 in acute myeloid leukemia;Meshinchi;Clin Cancer Res,2009

3. Differential impact of allelic ratio and insertion site in FLT3-ITD positive AML with respect to allogeneic hematopoietic stem cell transplantation;Schlenk;Blood,2014

4. Diversity of the juxtamembrane and TKD1 mutations (exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data;Schnittger;Genes Chromosomes Cancer,2012

5. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia;Smith;Nature,2012

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Age‐associated myeloid malignancies – the role of STAT3 and STAT5 in myelodysplastic syndrome and acute myeloid leukemia;FEBS Letters;2024-07-24

2. Comprehensive Insights that Targeting PIM for Cancer Therapy: Prospects and Obstacles;Journal of Medicinal Chemistry;2024-01-02

3. NADPH oxidase mediated oxidative stress signaling in FLT3-ITD acute myeloid leukemia;Cell Death Discovery;2023-06-30

4. Current Methods of Post-Translational Modification Analysis and Their Applications in Blood Cancers;Cancers;2021-04-16

5. Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence;Journal of Clinical Medicine;2020-09-11